Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery.

Nathalie C Bellocq1, Suzie H Pun, Gregory S Jensen

  • 1Insert Therapeutics, Inc., Pasadena, California, USA.

Bioconjugate Chemistry
|November 20, 2003
PubMed
Summary

Researchers developed a novel transferrin-targeted, cyclodextrin polymer nanoparticle system for efficient gene delivery to cancer cells. This targeted approach enhances therapeutic delivery for metastatic cancer applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery and Cryo-EM-Guided Development of a Neuropilin-2-Binding Aptamer for Receptor Antagonism.

Journal of the American Chemical Society·2026
Same author

Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Rapid and label-free isolation of human peripheral blood monocytes using a reversible CD36-binding aptamer for cell capture.

Biomaterials science·2025
Same author

Investigating PolySTAT's role in clot contraction and fibrin network mechanics.

Biomaterials science·2025
Same author

Efficient and Traceless Aptamer-Based Serial Selection of Naïve and Early Memory CD8 T Cells for CAR T Cell Therapy.

Advanced healthcare materials·2025
Same author

Lytic polyplex vaccines enhance antigen-specific cytotoxic T cell response through induction of local cell death.

Advanced therapeutics·2025

Area of Science:

  • Biotechnology and Nanomedicine
  • Cancer Therapeutics
  • Gene Delivery Systems

Background:

  • Transferrin receptor is overexpressed on many cancer cells, making it a viable target for tumor-specific drug delivery.
  • Cyclodextrin-based nanoparticles offer a platform for gene delivery, but require surface modification for enhanced targeting and stability.
  • Poly(ethylene glycol) (PEG)ylation improves nanoparticle stability in biological fluids.

Purpose of the Study:

  • To develop and characterize a transferrin-modified, cyclodextrin polymer nanoparticle system for targeted gene delivery to cancer cells.
  • To evaluate the efficiency and specificity of the transferrin-targeted nanoparticles in delivering nucleic acids.

Main Methods:

  • Synthesis of a transferrin-PEG-adamantane conjugate for nanoparticle surface modification.

Related Experiment Videos

  • Formation of nanoparticles via condensation of a cyclodextrin polycation with nucleic acid.
  • Self-assembly of the transferrin conjugate onto nanoparticles through host-guest inclusion complex formation.
  • Assessment of nanoparticle stability and transfection efficiency in K562 leukemia cells.

    • Main Results:

    • Transferrin modification via a transferrin-PEG-adamantane conjugate was successfully achieved.
    • The transferrin-modified nanoparticles demonstrated stability in physiologic salt concentrations at low modification levels.
    • Targeted nanoparticles significantly increased transfection efficiency in K562 leukemia cells compared to untargeted particles.
    • The enhanced transfection was confirmed to be transferrin receptor-mediated, as it was abolished by excess free transferrin.

    Conclusions:

    • Transferrin-modified cyclodextrin polymer nanoparticles represent a promising targeted gene delivery system for cancer therapy.
    • The developed system shows potential for systemic delivery of nucleic acid therapeutics for metastatic cancer.
    • The targeted approach offers enhanced specificity and efficiency for cancer cell transfection.